Work

P-994. Building a Culture of Stewardship: The Role of Infectious Diseases Pharmacists in Promoting Documentation Across Pharmacy Teams

Year: 2026

Type: article

Abstract: Background Antimicrobial stewardship (AS) initiatives are critical for combating antibiotic resistance, improving patient outcomes, and ensuring optimal use of antimicrobials. Despite national guidelines and regulatory support, consistent documentation of AS interventions across pharmacy teams remains a challenge. This study evaluates the impact of integrating an infectious diseases (ID) pharmacist into a pharmacy team on AS documentation practices in a large academic medical center. Methods This quasi-experimental pre-post study was conducted at University of Missouri Health, a 709-bed tertiary care academic hospital. The intervention involved onboarding a dedicated ID/ASP pharmacist in August 2023. Documentation of AS interventions was tracked using the Cerner electronic medical record and Power BI analytics from January 2023 to December 2024. Intervention volumes, types, and pharmacist contributions were analyzed using Mann-Whitney U and chi-square tests. Results Following the addition of the ID/ASP pharmacist, the average number of monthly documented interventions increased from 152.4 ± 52.2 to 387 ± 122 (p < 0.00001). The ID/ASP pharmacist independently contributed an average of 104.3 ± 30.6 interventions monthly. The types of interventions shifted significantly, with the ID pharmacist more frequently documenting high-impact activities such as de-escalation (p < 0.00001) and escalation (p < 0.00001), compared to general pharmacists who primarily documented dose adjustments and communication-related activities. Conclusion The integration of an ID/ASP pharmacist into the pharmacy team led to substantial improvements in both the frequency and complexity of documented interventions. These findings highlight the importance of pharmacist-driven stewardship and underscore how focused documentation efforts can foster a culture of accountability and clinical excellence in AS programs. Disclosures Blain Thayer, PharmD, BCIDP, AAHIVP, AbbVie Inc: Honoraria

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofaf695.1193

Authors: Blain Thayer, Taylor Steuber, Taylor Nelson, Mary Reese, Andres Acevedo Bran

Institutions: University of New Mexico Hospital, University of Missouri–Kansas City, University of Missouri, University of Missouri Health System

Language: English

Topic: Antibiotic Use and Resistance

Subfield: Applied Microbiology and Biotechnology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053